FLANDERS.BIO
InactiveActs, filings and financial milestones
2025
10-06
abbreviated format · 51 days before the deadline
24-03
Gazette deed
Merger: absorbed by FBMDissolution of the company · Auditor report · Accounting effect11 points ▸
Gazette deed
Merger: absorbed by FBM
Dissolution of the company · Auditor report · Accounting effect11 points ▸
- General meeting, 13-02-2025
- Merger, “fusie door overneming, fusievoorstel” (deed in Dutch), mentioned 2 times in the deed
- Other provision, “Kennisname fusievoorstel, EERSTE BESLISSING” (deed in Dutch)
- Other provision, “Kennisname en bespreking verslagen bedrijfsrevisor, TWEEDE BESLISSING” (deed in Dutch)
- Auditor report, “boekhoudnormen België, zonder voorbehoud” (deed in Dutch)
- Auditor report, “artikel 13:3 Wetboek van Vennootschappen en Verenigingen, verrichtingsvoorstel” (deed in Dutch)
- Other provision, “beperking gebruik revisorverslag, artikel 13:3 Wetboek van Vennootschappen en Verenigingen” (deed in Dutch)
- Merger, “fusie door overneming, gehele vermogen onder algemene titel” (deed in Dutch)
- Accounting effect, 01-01-2025
- Dissolution, “ontbinding zonder vereffening”, merger (deed in Dutch)
- Other provision, “uitreiking vóór registratie, artikel 173 1°bis Wetboek van registratierechten” (deed in Dutch)
23-01
Gazette deed
Resignation: Wouter Piepers (day-to-day manager)Appointments: Vibio, Montis Biosciences and 3 others · Permanent representatives: Patrik De Haes, Danny Gonnissen and 8 others22 points ▸
Gazette deed
Resignation: Wouter Piepers (day-to-day manager)
Appointments: Vibio, Montis Biosciences and 3 others · Permanent representatives: Patrik De Haes, Danny Gonnissen and 8 others22 points ▸
- Board meeting, 28-11-2024
- Director resignation, Wouter Piepers (day-to-day manager)
- Director appointment, Vibio (day-to-day manager)
- Permanent representative, Patrik De Haes
- Permanent representative, Danny Gonnissen
- Permanent representative, Philippe De Backer
- General meeting, 20-06-2024
- Other provision, “vierjarig mandaat ten einde, A” (deed in Dutch)
- Other provision, “vierjarig mandaat ten einde, C” (deed in Dutch), mentioned 3 times in the deed
- Permanent representative, Bernard Sagaert (representative)
- Permanent representative, Ann Meulemans (representative)
- Permanent representative, Kenneth Wils (representative)
- The act holds 10 more points.
2024
31-12
Financial
Weakest financial yearnet -€355,692
The net result drops to -€355,692, the lowest from 2018 to 2024.
24-07
Gazette deed
Permanent representatives: Marieke Vermeersch and Erik PresentResignation: Willem Dhooge (day-to-day manager) · Power of attorney6 points ▸
Gazette deed
Permanent representatives: Marieke Vermeersch and Erik Present
Resignation: Willem Dhooge (day-to-day manager) · Power of attorney6 points ▸
- Board meeting, 18-06-2024
- Permanent representative, Marieke Vermeersch
- Permanent representative, Erik Present
- Director in office, Galapagos NV (director)
- Director resignation, Willem Dhooge (day-to-day manager)
- Power of attorney, Marc Ost
18-07
abbreviated format · 13 days before the deadline
2023
31-12
Financial
Back to profitnet €13,149
The net result is €13,149, after one loss-making year.
14-08
Gazette deed
Resignations: Aphea.Blo NV (director) and Antieron NV (director)Permanent representatives: Isabel Vercauteren, Jan Schrooten and 5 others · Reappointment: Aphea.Bio NV (director) · Appointment: Newton Biocapital Partners BV (director)14 points ▸
Gazette deed
Resignations: Aphea.Blo NV (director) and Antieron NV (director)
Permanent representatives: Isabel Vercauteren, Jan Schrooten and 5 others · Reappointment: Aphea.Bio NV (director) · Appointment: Newton Biocapital Partners BV (director)14 points ▸
- General meeting, 27-04-2023
- Director resignation, Aphea.Blo NV (director)
- Director resignation, Antieron NV (director)
- Permanent representative, Isabel Vercauteren, mentioned 2 times in the deed
- Permanent representative, Jan Schrooten
- Director reappointment, Aphea.Bio NV (director)
- Director appointment, Newton Biocapital Partners BV (director)
- Permanent representative, Philippe De Backer
- Board meeting, 02-02-2023
- Permanent representative, Nathalie Van Den Haute
- Permanent representative, Jeroen Van den Bossche
- Board meeting, 30-03-2023
- The act holds 2 more points.
08-08
Gazette deed
Amendment of the articles · NameGeneral meeting2 points ▸
Gazette deed
Amendment of the articles · Name
General meeting2 points ▸
- General meeting, 16-06-2023
- General meeting, “éénparigheid van stemmen, statutenwijzigingen rechtsgeldig aangenomen” (deed in Dutch)
25-05
abbreviated format · 67 days before the deadline
2022
12-09
Gazette deed
Registered office moved from Sint-Denijs-Westrem to GentAppointments: Wouter Piepers, Flen Health Pharma NV and 2 others · Reappointments: BioMARIC NV, Biotalys NV and 3 others14 points ▸
Gazette deed
Registered office moved from Sint-Denijs-Westrem to Gent
Appointments: Wouter Piepers, Flen Health Pharma NV and 2 others · Reappointments: BioMARIC NV, Biotalys NV and 3 others14 points ▸
- Board meeting, 30-06-2022
- Director appointment, Wouter Piepers (ceo/algemeen directeur)
- Registered-office move, Technologiepark-Zwijnaarde 122, 9052 Gent
- General meeting, 30-06-2022
- Other provision, 30-06-2022, 8
- Other provision, “bestuurder”, 30-06-2022 (deed in Dutch), mentioned 8 times in the deed
- Director reappointment, BioMARIC NV (director)
- Director reappointment, Biotalys NV (director)
- Director reappointment, VIB VZW (director)
- Director reappointment, imec VZW (director)
- Director reappointment, Bioqube Ventures NV (director)
- Director appointment, Flen Health Pharma NV (director)
- The act holds 2 more points.
12-07
abbreviated format · 19 days before the deadline
Show earlier events
2021
31-12
Financial
Highest result from 2018 to 2024net €323,533 ▲0.5%
The operating result of €330,768 and the net result of €323,533 are both a record.
31-12
Financial
Equity above €1mequity €1.3m ▲33.9%
With a profit in every financial year since 2018, equity grows to €1.3m.
08-07
abbreviated format · 23 days before the deadline
2020
16-07
abbreviated format · 15 days before the deadline
2019
31-12
Financial
Equity above €500,000equity €631,585 ▲70.6%
With a profit in every financial year since 2018, equity grows to €631,585.
26-04
abbreviated format · 96 days before the deadline
2018
11-07
abbreviated format · 20 days before the deadline
2017
06-06
abbreviated format · 55 days before the deadline
2016
09-05
abbreviated format · 83 days before the deadline
2004
10-03
27 publications in the Belgian Official Gazette, the last on 24-03-2025
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank